GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: MOXR 0916 | MOXR0916 | pogalizumab (deleted INN) | RG7888 | RO7021608
Compound class:
Antibody
Comment: Vonlerolizumab (MOXR0916) was an investigational humanized anti-human OX40 monoclonal, with reported preclinical efficacy [1]. Genentech terminated their Phase 2 trial NCT03029832 and have discontinued further development.
|
| No information available. |
Summary of Clinical Use  |
| MOXR0916 is in early stage clinical trial in patients with solid tumours, as a monotherapy and in combination with the approved anti-PDL1 antibody atezolizumab. Click here to link to ClinicalTrials.gov's list of MOXR0916 trials. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03029832 | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy | Phase 2 Interventional | Genentech, Inc. | A note on this clonical trial record indicates that Genentech have made the decision to discontinue clinical development of MOXR0916 for business reasons. | |
